FDA Puts Lab-Developed Test Oversight Plans On Hold

After years of wrangling over lab-developed test regulations with laboratory lobbyists, FDA has put its plans to finalize a guidance that lays out its oversight framework for LDTs on hold as a new Congress and a new deregulation-focused president-elect is set to take the helm.

PCR strip test tubes and micropipette in genetics laboratory. Toned photo

[Editors' note: This story was updated Nov. 21 to clarify that FDA's email to stakeholders did not explicitly state that the agency is delaying the final LDT guidance.]

Six years after US FDA announced its plans to develop a framework for actively regulating laboratory developed tests...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Regulation

More from Policy & Regulation